Kym Anthony

An Ottawa life sciences firm has the green light to test the product in the world’s most populous country as it looks to reverse years of sustained losses.
Fortified by $7.5 million in fresh funding, company is hoping a new version of its flagship product designed for people will help it finally achieve a market breakthrough.